key: cord-0721104-gf4c85xp authors: Perić, Aleksandar; Vezmar Kovačević, Sandra; Barać, Aleksandra; Perić, Aneta V.; Vojvodić, Danilo title: Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis date: 2020-12-21 journal: Laryngoscope Investig Otolaryngol DOI: 10.1002/lio2.514 sha: 6e6082d371f78747d84e1d598f68dff5db0778b5 doc_id: 721104 cord_uid: gf4c85xp BACKGROUND: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). METHODS: Seventy‐eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. RESULTS: EPs 7630 increased concentrations of MCP‐1 (P = .001) and IP‐10 (P = .049) and decreased levels of MIP‐1α (P < .001), ENA‐78 (P < .001), and IL‐8 (P < .001). Roxithromycin increased levels of IP‐10 (P = .049) and decreased levels of MCP‐1 (P < .001), MIP‐1α (P < .016), ENA‐78 (P < .001), and IL‐8 (P < .001). Comparison of the non‐treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P < .001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. CONCLUSION: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. LEVEL OF EVIDENCE: 1b. caused by infection-stimulated production of inflammatory mediators. 1, 2 In most cases, the acute suppurative infection resolves promptly following a course of antibiotic therapy supplemented with adjuvant therapy of decongestants, antihistamines, and intranasal corticosteroid sprays. 3, 4 However, the role of inflammatory mediators in ABRS is not explored in detail. Bacterial infection of the nasal mucosa stimulates the production and release of variety of cytokines and chemokines in the respiratory epithelial cells. 1, 5 This bacterial infection induces multiple changes in the nasal mucosa, including infiltration and activation of various inflammatory cells, especially neutrophils and monocytes and defects in the host and adaptive immune defence functions. 1, 5 Macrolide antibiotics, for example, erythromycin, clarithromycin, azithromycin and roxithromycin, are well-known for decades as a good option in therapy of acute and chronic rhinosinusitis due to strong bacteriostatic and immunomodulatory effects. 1, 4, 5 They bind to the 50S subunits of the bacterial ribosome, inhibiting protein synthesis. 1, 5 Herbal medicines have been used for centuries for therapy of acute upper airway infections. Preparation from the roots of Pelargonium sidoides was used for generations in South Africa for treatment of respiratory and gastrointestinal infections, due to its antiviral and antibacterial actions. 6 More than seven decades later, this polyphenol-rich extract was finally developed in Germany with coding name EPs 7630. 6 According to the International Consensus Statement on Allergy & Rhinology: Rhinosinusitis and European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020, the use of extract from Pelargonium sidoides is recommended as an option in therapy of ARS. 1, 5 The immunomodulatory effects of this herbal drug are mediated mainly by stimulation of tumor necrosis factor alpha (TNF-α), interferon beta (IFN-β), IFN-γ and interleukin-10 (IL-10) production and reducing production of IL-6 and IL-15 in human respiratory tract epithelial cells. 6 Exclusion criteria were: <18 years or >65 years, nasal/paranasal sinus surgery within 6 months before study, systemic diseases (cystic fibrosis, Churg Strauss syndrome, Wegener's granulomatosis, etc.), symptomatic seasonal allergic rhinitis (after pollen exposure during the study), bronchial asthma, hypersensitivity to roxithromycin or to Pelargonium sidoides extract, patients taking anticoagulants and salicylates, patients with gastrointestinal and hepatobiliary diseases, the use of oral or topical antibiotics, antihistamines and corticosteroids within the 4 weeks before the start of the study, the use of mucolytic, decongestants and hypertonic seawater within the 7 days before the investigation, pregnancy, lactation, active cigarette smoking. Subjects were excluded if they had symptoms or signs of severe acute bacterial rhinosinusitis (fever > 38 C, persistent severe unilateral facial or tooth pain, facial swelling, profuse unilateral mucopurulent secretion and worsening of symptoms after initial improvement). The randomization was performed in accordance with the CONSORT statement. A hundred patients (n = 100) with mild-to-moderate ABRS, examined and treated in our ENT Department, were involved in the study. Seven (n = 7) refused to participate while 15 (n = 15) patients did not meet inclusion criteria. Seventy-eight (n = 78) patients were thus recruited and assigned to the group 1 (n = 26), group 2 (n = 26), and control group (n = 26) by randomization. We used a simple computer-generated randomization procedure to allocate the participants into groups. The participants were deemed eligible by the investigator who informed the nurse about the eligibility. The nurse than assigned the patient to group 1, 2 and control group using a computer-generated random allocation. The study profile is presented in Figure 1 . The ABRS patients from group 1 received herbal drug EPs 7630 oral tablets 3 × 20 mg/day (Umckalor, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany), 10 days in total. The patients from group 2 received roxithromycin oral tablets 2 × 150 mg/day (Roximisan, Slaviamed, Belgrade, Serbia), also for 10 days. The patients with control group did not receive any medication and all the patients with severe deterioration in nasal symptoms or endoscopic findings were excluded from further investigation. Both the investigators and the patients were aware of the drug being given or not given. The patients did not use other medications simultaneously with herbal drug/roxithromycin. F I G U R E 1 Randomization of study participants. One hundred patients (n = 100) with diagnosis of ABRS were selected to participate in the study. Five (n = 7) refused to participate and eleven (n = 15) patients did not meet inclusion criteria. Seventyeight (n = 78) patients were finally recruited and assigned by randomization to the group 1 (n = 26) and group 2 (n = 26) and control group (n = 26) Nasal fluid samples were obtained from all 78 ABRS patients, at the beginning of the study (day 0, visit 1) and again at day 10 (visit 2) after the start of study by absorption method. After the insertion of cotton wool stick (Institute for Virology, Vaccines and Sera, "Torlak," Belgrade, Serbia) into the nasal middle meatus for 5 minutes, as previously described, 11 Table 1 . Total symptom score (TSS), the sum of intensities of 5 rhinosinusitis symptoms (nasal obstruction, rhinorrhea, postnasal drip, facial pain/ pressure, loss of the sense of smell), as well as individual scores for each nasal symptom were assessed at the visit 1 and visit 2 by the same specialist, using a visual analogue scale (VAS) (0-10 cm; 0 = absent, 10 = maximum intensity). Patients indicated their symptoms' score to be from 0 to 3 were diagnosed as "mild ARS." Symptoms in the score range from 4 to 7 were diagnosed as "moderate ARS", while the scores from 8 to 10 with fever of above 38 C for at least 3 days were diagnosed as "severe ARS." The patients with severe disease were excluded from investigation. During the investigation, patients recorded their symptom scores and noted the use of medications on diary cards and the investigator recorded scores at the visit 2. The investigator evaluated compliance of the treatment by insight into the diary cards. TSS of control subjects was also assessed. At visits 1 and 2, an experienced rhinologist evaluated the presence of mucosal edema and secretion in the middle meatus by use of nasal endoscopy (4 mm 0 endoscope, Karl Storz-Endoscope SE & Co, Tuttlingen, Germany). Four-point scales were used for assessment of endoscopic findings, according to the Pfaar et al. 12 Mucosal edema scored from 0 (no edema) to 3 (severe edema); middle meatus secretion from 0 (none) to 3 (profuse). The maximum Total Endoscopic Score (TES) was 12, bilaterally. According to the current guidelines, radiological examinations (X-ray, CT, MRI) were not used in the diagnostics of ABRS. 1,2 Reported adverse events were recorded throughout the study, with severity grades as mild, moderate and severe. At visit 2, nasal examination, laboratory tests and vital signs assessment were performed. All patients were aware of potential adverse effects of herbal medication or roxithromycin. Therefore, the development of any medical complications associated with progression of ABRS (orbital, endocranial or bone complications) was also recorded during the study. We performed a power analysis with the use of the G*Power 3.1.9 programme (Heinrich Heine Univerität, Düsseldorf, Germany). For the effect size of 0.4 the type I error (α level) .05, the power of 80%, and the comparison of three groups with two measurements for each group, a total of 66 participants was calculated (22 per group). We calculated a T A B L E 1 Sensitivity of detection, assay range and coefficient of variation for investigated mediators drop-out rate of 20% and therefore included 26 patients in each group. The parameters were expressed as mean ± SD. For comparison between the groups, the non-parametric Kruskal-Wallis test was used. If the test revealed significant difference among groups the Mann-Whitney U test was further used to detect differences between groups. For paired comparisons in a group, we used the Wilcoxon's test. To calculate the relative changes of each parameter, we used the formula: posttherapeutic value-pretherapeutic value/pretherapeutic value. P values < .05 were considered significant. No adjustments for multiplicity were applied. The analysis was done by using the Statistical Package for the Social Sciences, version 15.0 software (SPSS Inc., Chicago, Illinois). Baseline demographic characteristics of ABRS patients after randomization are presented in Table 2 . Clinical parameters at visit 1 and visit T A B L E 2 Baseline demographic characteristics of ABRS patients, after randomization. They were divided into patients without treatment, patients treated by EPs 7630 and those treated by roxithromycin .372 Parameter Controls (n = 26) Mean ± SD (range) EPs 7630 (n = 26) |Mean ± SD (range) P value Kruskal-Wallis test NO Visit 1 6.5 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) .975 Visit 2 6.9 ± 0.3 (5-7) 3.1 ± 0.4 (2-4) 2.1 ± 0.7 (2-3) <.001 RH Visit 1 6.4 ± 0.9 (4-7) 6.5 ± 0.6 (5-7) 6.6 ± 0.5 (6-7) .768 Visit 2 6.9 ± 0.3 (6-7) 3.4 ± 0.8 (2-5) 3.5 ± 0.8 (2-5) <.001 PD Visit 1 6.6 ± 0.6 (5-7) 6.4 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) .624 Visit 2 6.8 ± 0.4 (6-7) 3.0 ± 0.6 (2-4) 2.9 ± 0.7 (2-5) <.001 FPP Visit 1 6.5 ± 0.8 (5-7) 6.5 ± 0.5 (6-7) 6.7 ± 0.7 (4-7) .147 Visit 2 6.6 ± 0.6 (6-7) 3.0 ± 0.3 (2-4) 2.1 ± 0.6 (2-4) <.001 LSS Visit 1 6.4 ± 0.8 (5-7) 6.6 ± 0.6 (5-7) 6.4 ± 0.6 (5-7) .384 Immunomodulatory actions of this drug are also interesting. A large body of evidence indicates that induction of non-specific host defence mechanisms against a number of pathogens, especially bacteria and viruses, is related to the production of IFN-β and IFN-γ. Previous in vitro investigations demonstrated an up-regulation of these cytokines, as well as TNF-α after the stimulation of human macrophages, lymphocytes and epithelial cells with Pelargonium sidoides extract. [6] [7] [8] [9] We found significant improvement for all symptoms and endoscopic findings in our patients after the use of this herbal medicine. However, these clinical effects were better in patients treated by roxithromycin, except for the rhinorrhea and postnasal drip. This finding suggests that roxithromycin and EPs 7630 almost equally suppress According to our results, none of the patients reported adverse events. However, there have been reports of allergic reactions, liver toxicity and hemorrhage after treatment with Pelargonium sidoides extract. 23, 24 There is a theoretical risk of interactions with anticoagulants such as warfarin, and antiplatelet drugs such as aspirin. There are also cautions against use of the tested substance by patients with serious liver diseases or during pregnancy. 23, 24 Allergic reactions and gastrointestinal symptoms are main side effects after the use of macrolide antibiotics. 5, 17 This study has some limitations. It was an open label study based on the assessment of symptoms and endoscopic findings. Therefore, due to our financial limitations, we performed only biochemical Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg Acute sinusitis: a histopathological and immunohistochemical study Current healthcare pathways in the treatment of rhinosinusitis in Germany European position paper on rhinosinusitis and nasal polyps 2020 Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection trough modulation of viral binding proteins on human bronchial epithelial cells In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs ® 7630 Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial Antimicrobial, antiviral and immunomodulatory activity studies of Pelargonium sidoides (EPs ® 7630) in the context of health promotion Immune response induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15 Nonselective chemokine levels in nasal secretions of patients with perennial nonallergic and allergic rhinitis Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial Cytokines in nasal polyposis, acute and chronic sinusitis Nasal biomarker profiles in acute and chronic rhinosinusitis Cytokine patterns and endotypes in acute and chronic rhinosinusitis Immunomodulatory effects of antimicrobial drugs Role of antibiotics in sinusitis IFNgamma-inducible protein 10 (IP-10, CXCL10)-deficient mice reveal a role for IP-10 in effector T-cell generation and trafficking Cloning and characterization of the human neutrophil-activity peptide (ENA-78) gene Validation of the nasal mucus index, a novel measurement of acute respiratory infection severity Macrophage inflammatory protein-1 The effect of neutrophil serine proteases on human nasal epithelial cell barrier function Allergic reactions to medicines derived from Pelargonium species Pelargonium sidoides extract for treating acute respiratory tract infections The authors declare no conflict of interest. Aleksandar Peri c https://orcid.org/0000-0002-8453-7272 BIBLIOGRAPHY